An Unusual Case of Anti-Glomerular Basement Membrane Disease and Phospholipase A2 Receptor-Associated Membranous Nephropathy After Exposure to Hydrocarbons

Am J Kidney Dis. 2024 Jan;83(1):112-115. doi: 10.1053/j.ajkd.2023.07.011. Epub 2023 Sep 14.

Abstract

We present a rare case of a patient with toluene exposure manifesting as anti-glomerular basement membrane (GBM) disease on a background of phospholipase A2 receptor (PLA2R)-associated membranous nephropathy. A 23-year-old man presented to the emergency department with hypertension, headache, hemoptysis, anemia, acute kidney injury, glomerular hematuria, and proteinuria. He endorsed repeated exposure to toluene-containing products while repairing dirt bikes. Serologies were positive for anti-GBM antibodies. Kidney biopsy showed crescentic glomerulonephritis with linear immunoglobulin G and granular PLA2R staining by immunofluorescence. He was initially treated with high-dose steroids, plasmapheresis, and hemodialysis for pulmonary-renal syndrome followed by oral cyclophosphamide and prednisone, which were discontinued after 3 months when follow-up biopsies confirmed little chance for renal recovery. He remained on dialysis 1 year later. This case exhibits a unique presentation of anti-GBM syndrome and underlying membranous nephropathy following repeated hydrocarbon exposure. Inhaled toxins promote recurrent localized inflammation, unmasking previously hidden epitopes. Early diagnosis and appropriate use of immunosuppressive and extracorporeal therapies are necessary to prevent morbidity and to improve survival in this rare condition.

Keywords: Anti–glomerular basement membrane glomerulonephritis; Case report; Goodpasture syndrome; Hydrocarbon exposure; Membranous nephropathy.

Publication types

  • Case Reports

MeSH terms

  • Anti-Glomerular Basement Membrane Disease* / chemically induced
  • Anti-Glomerular Basement Membrane Disease* / complications
  • Anti-Glomerular Basement Membrane Disease* / diagnosis
  • Autoantibodies
  • Cyclophosphamide / therapeutic use
  • Glomerulonephritis, Membranous* / chemically induced
  • Glomerulonephritis, Membranous* / diagnosis
  • Glomerulonephritis, Membranous* / drug therapy
  • Humans
  • Male
  • Phospholipases / therapeutic use
  • Polyesters / therapeutic use
  • Receptors, Phospholipase A2
  • Toluene / therapeutic use
  • Young Adult

Substances

  • Autoantibodies
  • Cyclophosphamide
  • Phospholipases
  • Polyesters
  • Receptors, Phospholipase A2
  • Toluene